Company Insights

ADXN supplier relationships

Explore interactive graphBrowse insights index
ADXN supplier relationship map

Addex Therapeutics (ADXN): A concise supplier and partner profile for investors

Addex Therapeutics is a Geneva-based, developing-stage biopharmaceutical company that discovers and develops small-molecule therapies for central nervous system disorders. The company monetizes primarily through research collaborations, licensing of intellectual property, milestone-based partnership revenues, and selective equity investments in biotech peers that can advance shared programs or create strategic optionality. For investors and operators evaluating supplier relationships, the strategic picture is clear: Addex leverages external chemistry and preclinical capabilities while relying on licensing and partnerships to convert R&D into near-term value.
Explore supplier intelligence and structured partner summaries at https://nullexposure.com/.

How Addex runs the business and why suppliers matter

Addex operates as a lean, asset-centric biotech. Financials show limited recurring revenue (Revenue TTM ≈ $158k) and persistent operating losses (EBITDA ≈ -$2.46M; diluted EPS ≈ -9.05), which makes external relationships and licensing cash flows central to the firm’s operating model. Contracts and collaborations function as the company’s de‑risking engine: chemistry, ADME/PK, and preclinical profiling are outsourced to specialist providers while Addex focuses on program definition, clinical advancement, and IP management.

  • Contracting posture: partner-centric and collaborative; Addex structures research collaborations and licensing agreements rather than owning large in‑house development platforms.
  • Concentration: supplier exposure is concentrated—few named partners provide critical capabilities, elevating supplier leverage in the short term.
  • Criticality: relationships that furnish medicinal chemistry, ADME/PK, and preclinical profiling are operationally critical to advancing assets towards clinical entry.
  • Maturity: Addex is an early-stage developer; many relationships are oriented toward preclinical and Phase II readiness rather than late-stage commercialization.

These characteristics make supplier diligence a top priority for investors who want to translate program milestones into valuation inflection points. For deeper supplier mapping and monitoring, visit https://nullexposure.com/.

The partner map: what each relationship means for value creation

Below are the company’s disclosed supplier and partner relationships drawn from Addex’s recent earnings calls and news coverage. Each entry includes a concise, plain-English summary and the cited source.

Sinntaxis — collaborative preclinical profiling partner

Addex is working with Sinntaxis to complete preclinical profiling of dipraglurant and to prepare the clinical studies, making Sinntaxis a direct contributor to program readiness. This relationship is described in Addex’s Q3 2025 earnings call as part of a broader research collaboration. (Addex Q3 2025 earnings call)

University of Lund — academic research collaborator

The University of Lund is named as a collaborator alongside Sinntaxis in completing preclinical profiling of dipraglurant, signaling academic support for translational work and access to specialized scientific expertise. (Addex Q3 2025 earnings call)

Stalicla — strategic equity investment into a clinical-stage specialist

In June 2025 Addex disclosed an investment in Stalicla, a private clinical-stage company focused on neurodevelopmental disorders, indicating Addex uses minority investments to secure strategic optionality and scientific alignment. (Addex Q2 2025 earnings call)

Johnson & Johnson (JNJ) — returned asset rights and portfolio control

Addex announced it regained rights to the mGlu2 positive allosteric modulator program, including Phase II asset ADX71149, from Johnson & Johnson—an event that restores program control and future licensing or development flexibility to Addex. (Addex Q2 2025 earnings call)

Enamine Ltd — outsourced chemistry and ADME/PK support

Enamine provides integrated medicinal chemistry, pharmacology and ADME/PK capabilities to support Addex’s small-molecule CNS programs, positioning Enamine as a key outsourced supplier for compound generation and preclinical evaluation. (StockTitan overview, FY2025)

Neurosterix Group — in-kind services and patent maintenance support

Addex recorded income related to the fair value of services received from Neurosterix Group at no cost, and noted patent maintenance activity funded by Indivior; Neurosterix’s contribution is therefore an operational service input recognized in Q3 2025 results. (InsiderMonkey coverage of Q3 2025 earnings call transcript / Q3 2025)

What these relationships say about operational risk and upside

The roster of partners demonstrates a deliberate mix of academic collaborators, specialised service providers, and corporate counterparties:

  • Operational leverage: Outsourcing chemistry, ADME/PK and preclinical profiling reduces fixed cost but concentrates program delivery risk in a small number of third parties. Failure or delay at any of these suppliers would have material program impact.
  • Value capture: Regaining rights from J&J is a positive value-capture event that increases optionality for licensing, partnerships, or value realization through clinical progress.
  • Capital efficiency: The Stalicla equity stake and in-kind services from Neurosterix are consistent with a cash-conserving strategy that uses non-dilutive service arrangements and strategic minority investments to extend runway.
  • Market signal: Financial ratios (EV/Revenue ≈ 139.2; Price/Sales ≈ 53.46) reflect the tiny revenue base relative to enterprise value and the binary, milestone-driven valuation typical of early-stage biotechs.

Investors should prioritize supplier continuity clauses, milestone and deliverable definitions, and IP assignment terms when assessing Addex’s partnership agreements.

Practical due diligence checklist for operators and investors

To convert supplier visibility into investment conviction, focus diligence on these items:

  • Confirm contractual deliverables and timelines for Sinntaxis, Enamine and University of Lund work packages.
  • Validate IP ownership and reversion terms—especially relevant after the J&J rights reversion.
  • Review financial exposure and contingency plans if a key supplier misses a milestone.
  • Assess the commercial optionality that Addex now controls for ADX71149 following the J&J exit.

For structured supplier intelligence and ongoing monitoring, see https://nullexposure.com/.

Bottom line: where the value drivers and risks sit

Addex is a small, partner‑dependent CNS specialist whose near-term prospects hinge on successful preclinical-to-clinical execution and the monetization of regained assets. Key value drivers are partnership execution, milestone realization, and IP commercialization — key risks are supplier concentration and the company’s modest revenue base. For investors and operating partners, the critical work is in the contracts and the execution timetable: verify obligations, timelines, and IP flow to assess how supplier performance translates into valuation milestones.

For a regular supply‑chain view of small-cap biotech partners and up-to-date relationship tracking, visit https://nullexposure.com/.